Kardi Ai Raises Over €5.3M for ECG Monitoring Expansion

A monthly email is part of Kardi Ai’s heart-monitoring service. Alongside a chest strap and an app, the company gives a user a record of measurements that a doctor can return to, turning time spent outside the clinic into information available at the next conversation about care.

The Olomouc, Czech Republic medtech company has raised over €5.3M in Series A financing led by Callisto Health, according to participating investor Slovenská sporiteľňa. Announced on November 11, the round supports expansion across Europe and Asia and development of predictive cardiac models. The investment backs both a service already in use and research intended to extend what clinicians can learn from repeated ECG recordings.

That combination gives the financing its practical significance. Kardi Ai is carrying a relationship among patient, software and physician into more health systems, while pursuing a new capability that will need its own clinical validation and regulatory approval.

The Series A follows a service into new markets

Callisto Health led the round with participation from the Seed Starter programmes of Česká spořitelna and Slovenská sporiteľňa, BrightCap Ventures, Purple Ventures, DEPO Ventures and Garage Angels. The Slovak bank disclosed a €500K investment. Kardi Ai separately reported a €23M valuation in its company announcement, an ownership-pricing measure that should remain distinct from the money entering the business.

The investor announcement reports more than 6,000 users, relationships with over 70 Czech hospitals and more than 20 corporate and employee-benefit partners. Those figures describe reported reach across several channels. They leave open how much revenue each channel produces, how frequently individual users measure and how the commercial arrangements differ among hospitals, employers and people buying directly.

For operators reading the round, those distinctions help explain the work around expansion. A patient can buy equipment through an online channel, yet the value of an ECG record also depends on somebody being able to interpret it and decide how it fits into care. Adding distribution gives a medical-technology business another route to the user; building a useful continuing service asks more of the company after the sale.

The presence of bank venture programmes alongside specialist and early-stage investors brings several institutional perspectives into that work. Their participation establishes who backed the financing. It does not establish a new reimbursement agreement, a hospital procurement contract or an exclusive route into a national healthcare system.

Repeated ECG measurements create a continuing clinical handoff

Kardi Ai’s product combines an ECG chest strap, mobile software and AI analysis of recordings. The English product page identifies a Polar H10 sensor and describes measurement history available to users and their doctors, with a recurring report sent by email. An intermittent rhythm disorder can fall outside a short examination window, giving repeated recordings a specific purpose in the clinical information chain.

A cardiologist still has to turn that information into a decision about the patient. The company describes its device as supporting detection of selected rhythm disorders and assisting diagnosis and monitoring. That scope matters when AI enters the story: an analysis delivered through an app belongs inside a care process, and a financing announcement supplies no reason to describe it as an autonomous physician.

The company’s certification page states that Kardi Ai is a Class IIa medical device under European MDR legislation. Medical-device certification is also a distinct technology-business category, as DevCuration’s coverage of Scarlet’s certification financing illustrates. This is the disclosed status of Kardi Ai’s existing product. The models planned to estimate future arrhythmia risk are a further development effort, with validation and approval requirements attached to their intended medical use.

Commercially, the continuing handoff is an important part of what Kardi Ai is offering. Hardware creates the recording opportunity, while software organizes a growing history around a person. As the company reaches new users, the practical question follows that history into the doctor’s working day: how will the additional information help the next decision, and how will the service keep it accessible?

Clinical and technical experience sit inside the founding team

Kardi Ai’s account of its origins begins with neighbors Stephen Burke and cardiologist Tomáš Skála discussing the difficulty and cost of monitoring heart problems. The company, founded in 2022, now lists Tomáš Skála as a co-founder and research director, Pavel Digaňa as co-founder and technical director, and David Skála as co-founder and product director. Burke remains identified as a co-founder.

Vlastimil Hrabal is the current CEO and co-founder, as confirmed in the investor’s funding announcement and his current professional profile. Digaňa’s profile identifies his role as CTO. Those responsibilities put clinical expertise, product decisions, software architecture and international operations inside the same leadership group, a relevant combination for a service that must work for the person wearing it and the clinician receiving its output.

The team’s next research assignment reaches further into time. Predictive models would seek to estimate the risk of an arrhythmia before an episode appears, using information from multiple measurements. Tech.eu’s reporting makes clear that these capabilities remain in development and require clinical validation and regulatory approval before introduction into medical practice.

For Kardi Ai, that means the expansion of the current service and the development of future prediction can progress on different schedules. A hospital relationship can help the business understand a local workflow while researchers establish what a future model can support. Each has its own evidence to produce, and each gives the company a different reason to stay close to clinicians.

Expansion brings local delivery into the investment story

Germany is an immediate expansion priority following pilots, building on Kardi Ai’s presence in Czechia, Slovakia, Poland, Romania and Bulgaria. Vestbee’s November 12 report also describes plans for India, the United Arab Emirates and Singapore. These are market-development plans with country-specific commercial and regulatory work, rather than evidence that every planned market already contributes customers or revenue.

The geography matters because the same ECG technology reaches patients through different institutions and relationships. A distributor, an employer programme and a cardiology practice may each help introduce the service, while answering different questions about purchasing, support and follow-up. Replicating the device leaves those questions available for local teams to solve.

Kardi Ai’s financing therefore reaches into both science and service delivery. More capital can support clinical validation and entry into another market, while the company’s day-to-day relevance continues to depend on whether recordings reach people able to use them. The monthly report, the app history and the next appointment remain connected parts of that assignment as Hrabal’s team brings another group of doctors and patients into the service.